Rimiducid

N/A

Report date: 2026/04/25 20:00:23
NME

Base Information

Drug NameRimiducid
Drug Alias Name利米多赛Rimiducidum利米度塞AP-1903
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFK506-binding protein 1A ligand
TargetsFK506-binding protein 1A
Therapy Area/IndicationsUveal melanomaBlastic Plasmacytoid Dendritic Cell NeoplasmSolid tumours +[43] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAriad Pharmaceuticals IncBellicum Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesPhoenix SENOLYTIX IncBellicum Pharmaceuticals IncThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesNational Cancer InstituteRegeneron Pharmaceuticals Inc
Active IndicationsSolid tumoursCytopeniaImmunoproliferative Disorders +[16] 
Inactive IndicationsUveal melanomaBlastic Plasmacytoid Dendritic Cell NeoplasmGraft vs Host Disease +[27] 

Other Information

ATC CodeN/A
Related LinksN/A